Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple diet switch calm IBS? a trial puts two popular eating plans to the test.

NCT ID NCT07722572

Completed Symptom relief Sponsor: Antalya Bilim University Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial compares two diets—low-FODMAP and lactose- and gluten-free—in adults with irritable bowel syndrome (IBS). Each participant tries both diets for four weeks, with a one-week break in between, to see which one better reduces gut symptoms and improves mental health. The goal is to find out whether one diet offers clearer benefits for people struggling with IBS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a low-FODMAP diet and a lactose- and gluten-free diet
What this could lead to
If one diet clearly outperforms the other, this could help doctors recommend a simpler or more effective first-line dietary approach for IBS.
What could go wrong
This is a relatively small crossover trial with only 72 participants, so results may not apply to everyone with IBS. Dietary adherence can be challenging, and the one-week washout may not fully reset gut symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IRRITABLE BOWEL SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IRRITABLE BOWEL SYNDROME

Contacts and locations

Locations

  • Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Gastroenterology

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.